- American City Business Journals•2 months ago
Hemispherx Biopharma Inc. has obtained intellectual property rights for its two products, one approved and one under development, held by its former CEO. The former CEO, Dr. William A. Carter, was fired by the board of the Philadelphia biotechnology company in February. The assignment of the intellectual property rights by Carter follows the company reaching a settlement with Carter on his wrongful termination lawsuit filed in March.
- American City Business Journals•4 months ago
Hemispherx BioPharma, in its first deal since the company’s new management, pledged to seek more partnerships, has entered into an agreement with a Saudi Arabian drug company. The clinical trial, sales, marketing, distribution, and supply agreement was signed by Philadelphia-based Hemispherx and Scientific Products Pharmaceutical Co. Ltd. in Riyadh. The contract — which covers Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar, and Bahrain — calls for Scientific Products to purchase certain undisclosed quantities of Hemispherx’s clinical grade interferon alfa-n3 for investigative use in individuals who are exposed to and show early onset symptoms of the coronavirus that causes MERS.
|Bid||0.13 x 800|
|Ask||0.13 x 100|
|52wk Range||0.06 - 0.20|
|Day's Range||0.12 - 0.13|
|Avg Vol (3m)||584,422|
As of 10:36 AM EDT. NYSE MKT Real Time Price. Market open.